Work

Su1739 RISANKIZUMAB, BUT NOT USTEKINUMAB OR VEDOLIZUMAB, DOWNREGULATES IL-23-INDUCED MUCOSAL PATHOGENIC TH17 CELLS IN PATIENTS WITH CROHN'S DISEASE

Year: 2024

Type: conference-abstract

Source: Gastroenterology

DOI: 10.1016/s0016-5085(24)02303-5

Authors: Daniele Noviello, Irene Dusetti, Valerie L. Pivorunas, Francesco Simone Conforti, Chiara Amoroso, Clorinda Ciafardini, Ambra E. Lovati, Maurizio Vecchi, Federica Facciotti, Moira Paroni, Flavio Caprioli

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396644175

Cites:

Cited by:

Related to: 10